

Revision date: 26-Mar-2019 Version: 2.1 Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Heparin Sodium Injection, Sterile Solution, USP

Trade Name: Heparin Sodium Injection, USP

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as anticoagulant agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc

235 East 42nd Street New York, New York 10017

Emergency telephone number:

1-800-879-3477

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom

+00 44 (0)1304 616161 Emergency telephone number:

International Chemtrec (24 hours): +1-703-527-3887

Chemtrec (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see

Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS	GHS Classification	%
		List		

2704440

Material Name: Heparin Sodium Injection, Sterile Solution, Page 2 of 7

USP

Revision date: 26-Mar-2019 Version: 2.1

3. COMPOSITION / INFORMATION ON INGREDIENTS						
Dalteparin Sodium (Heparin Sodium)	9041-08-1	Not Listed	Not Listed	1,000-10,000		
				units/mL		
Water	7732-18-5	231-791-2	Not Listed	*		

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this

mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Exposure:

Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion This material produces toxic fumes of nitrogen and sulfur oxides, carbon dioxide, and carbon

Products: monoxide during fires.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Material Name: Heparin Sodium Injection, Sterile Solution, Page 3 of 7

USP

Revision date: 26-Mar-2019 Version: 2.1

Measures for Cleaning /

Collecting:

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Additional Consideration for

Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical product used as anticoagulant agent

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Dalteparin Sodium (Heparin Sodium)

Pfizer OEL TWA-8 Hr: 200µg/m³

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective

Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and

specific operational processes.

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations. (Protective clothing must meet the standards in accordance

with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international

equivalent.)

Material Name: Heparin Sodium Injection, Sterile Solution, Page 4 of 7

USP

Revision date: 26-Mar-2019 Version: 2.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solution Color: Colorless to pale straw-

color

Odor: No data available. Odor Threshold: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

Solvent Solubility:
Water Solubility:
Solubility:
Solubility:
Soluble: Water
PH:
No data available
Soluble: Water
5.0-7.5

Melting/Freezing Point (°C):

Boiling Point (°C):

No data available.

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Water

No data available

Dalteparin Sodium (Heparin Sodium)

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available

Flammablity:

Autoignition Temperature (Solid) (°C):

Flammability (Solids):

Flash Point (Liquid) (°C):

Upper Explosive Limits (Liquid) (% by Vol.):

Lower Explosive Limits (Liquid) (% by Vol.):

No data available
No data available
No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

Products:

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Short Term: May cause eye irritation (based on components) May produce allergic reactions following skin

contact

Known Clinical Effects: Clinical use of this drug has caused hemorrhage, gastrointestinal bleeding, increased bleeding

time. Individuals sensitive to this material or other materials in its chemical class may develop

allergic reactions.

Material Name: Heparin Sodium Injection, Sterile Solution, Page 5 of 7

USP

Revision date: 26-Mar-2019 Version: 2.1

11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Dalteparin Sodium (Heparin Sodium)

Rat Oral LD 50 > 5000 mg/kg Mouse Oral LD 50 > 5000mg/kg

Mouse Intraperitoneal LD 50 > 2500mg/kg
Rat Intraperitoneal LD 50 2500mg/kg
Mouse Intravenous LD 50 2800mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Dalteparin Sodium (Heparin Sodium)

Eye Irritation Rabbit Mild

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Dalteparin Sodium (Heparin Sodium)

Fertility and Embryonic Development Rat Subcutaneous 10 mg/kg/day NOAEL Fertility, Fetotoxicity

Embryo / Fetal Development Rat Intravenous 10,000 mg/kg/day LOAEL Fetotoxicity Embryo / Fetal Development Rabbit Intravenous 2,500 mg/kg/day LOAEL Fetotoxicity

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

Material Name: Heparin Sodium Injection, Sterile Solution, Page 6 of 7

USP

Revision date: 26-Mar-2019 Version: 2.1

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Dalteparin Sodium (Heparin Sodium)

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling

Not Listed

Not Listed

Present

Present

Schedule 4

for Drugs and Poisons:

EU EINECS/ELINCS List Not Listed

Water

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

16. OTHER INFORMATION

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information.

Material Name: Heparin Sodium Injection, Sterile Solution, Page 7 of 7

USP

Prepared by:

Revision date: 26-Mar-2019 Version: 2.1

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal

Protection.

Revision date: 26-Mar-2019

Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
